Guideline for the use of beta-interferons in patients with multiple sclerosis - A South African proposal

South African Medical Journal

Volumn 94, Issue 11, 2004, Pages 917-921

  Modi, G ^a  

^a NONE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM; GAMMA INTERFERON; GLATIRAMER; INTERFERON; INTERFERON BETA SERINE; METHYLPREDNISOLONE; STEROID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PROTOCOL; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MEDICAL SPECIALIST; MULTIPLE SCLEROSIS; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREGNANCY; RELAPSE; SIDE EFFECT; SOUTH AFRICA;

ADJUVANTS, IMMUNOLOGIC; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SOUTH AFRICA;

EID: 9444274009     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Poser C, Paty D, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
2. McDonald WI, Comestan A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
3. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: Clinical results of a randomised, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
4. PRISMS Study Group. Randomised double-blind placebo-controlled study of beta-1a in remitting relapsing multiple sclerosis. Lancet 1998; 352: 1498-1504.
5. The PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long term efficacy of interferon beta-1a in relapsing MS. Neurology 2001; 56: 1628-1636.
6. European Study Group on Interferon beta-1b in Secondary Progessive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.
7. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-1504.
8. Goodkin DE, and the North American Study Group on Interferon beta-1b in secondary progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomised controlled trial. Neurology 2000; 54: 2352.
9. Cohen JA, Goodman AD, Heidenreich FR, et al. Results of IMPACT, a phase 3 trial of interferon beta-1-a in secondary progressive multiple sclerosis. Neurology 2001; 56: S20.003.